AP
HRTX icon

Anchyra Partners’s Heron Therapeutics HRTX Stock Holding History

Anchyra Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,043
Closed -$14.4K – 363
2026
Q1 		$14.4K Buy
+18,043
New +$20.9K ﹤0.01% 275

Other funds holding HRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AR
Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return

Anchyra Partners's HRTX Position: Q2 2026 in Review

Anchyra Partners sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 18,043 shares — an estimated $14.4K sold.

Anchyra Partners first reported a position in HRTX in Q1 2026 and held it in 1 quarter. The position peaked at $14.4K in Q1 2026. 67 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Anchyra Partners reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Anchyra Partners sold 18,043 Heron Therapeutics shares in Q2 2026, an estimated $14.4K.
  • Anchyra Partners first reported a position in Heron Therapeutics in Q1 2026 and held it in 1 quarter.
  • Anchyra Partners's Heron Therapeutics position peaked at $14.4K in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.